{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T23:52:21Z","timestamp":1790121141520,"version":"4.0.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T00:00:00Z","timestamp":1612569600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T00:00:00Z","timestamp":1612569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Neutropenia, a decrease in total number of neutrophils below 1500\/mm<jats:sup>3<\/jats:sup> and particularly severe neutropenia, defined as neutrophils less than 500\/mm<jats:sup>3<\/jats:sup>, is a potential adverse effect of antipsychotic medications that can lead to increased risk of infections and death. However, much of the attention on the potential adverse effect is centered exclusively on clozapine, which remains the only antipsychotic medication in the United States requiring standardized monitoring of blood work. We demonstrate here that paliperidone can also cause neutropenia and therefore clinicians should be aware of this possibility especially during initiation of treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>The following report presents the case of a 23-year-old African American male with first episode psychosis who developed neutropenia after initiation of paliperidone. Neutropenia resolved after discontinuation of paliperidone and initiation of an alternative antipsychotic, haloperidol.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This case report demonstrates an example of paliperidone induced neutropenia which resolved with a switch to haloperidol. We conclude that when initiating paliperidone, clinicians should be more aware of the risk of neutropenia. Moreover, neutropenia may be a more common and overlooked issue in patients on antipsychotic medications other than clozapine and increased awareness of comparative risk across antipsychotics could help direct treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12888-021-03073-w","type":"journal-article","created":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T18:37:11Z","timestamp":1612809431000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Paliperidone induced neutropenia in first episode psychosis: a case report"],"prefix":"10.1186","volume":"21","author":[{"given":"Natalie","family":"Martos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Marhefka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W.","family":"Sedlak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Frederick C.","family":"Nucifora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,6]]},"reference":[{"issue":"4","key":"3073_CR1","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1192\/bjp.169.4.483","volume":"169","author":"K Atkin","year":"1996","unstructured":"Atkin K, Kendall F, Gould D, Freeman H, Liberman J, O'Sullivan D. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry. 1996;169(4):483\u20138. https:\/\/doi.org\/10.1192\/bjp.169.4.483.","journal-title":"Br J Psychiatry"},{"issue":"3","key":"3073_CR2","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1007\/s13311-017-0552-9","volume":"14","author":"FC Nucifora Jr","year":"2017","unstructured":"Nucifora FC Jr, Mihaljevic M, Lee BJ, Sawa A. Clozapine as a model for antipsychotic development. Neurotherapeutics. 2017;14(3):750\u201361. https:\/\/doi.org\/10.1007\/s13311-017-0552-9.","journal-title":"Neurotherapeutics."},{"issue":"Suppl. 3","key":"3073_CR3","first-page":"3","volume":"59","author":"G Honigfeld","year":"1998","unstructured":"Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry. 1998;59(Suppl. 3):3\u20137.","journal-title":"J Clin Psychiatry"},{"key":"3073_CR4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1756-8722-3-24","volume":"3","author":"MA Bautista-Quach","year":"2010","unstructured":"Bautista-Quach MA, Liao YM, Hsueh CT. Pancytopenia associated with clonazepam. J Hematol Oncol. 2010;3:24. https:\/\/doi.org\/10.1186\/1756-8722-3-24.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"3073_CR5","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1089\/cap.2011.0136","volume":"23","author":"KN Maher","year":"2013","unstructured":"Maher KN, Tan M, Tossell JW, Weisinger B, Gochman P, Miller R, Greenstein D, Overman GP, Rapoport JL, Gogtay N. Risk factors for neutropenia in clozapine-treated children and adolescents with childhood-onset schizophrenia. J Child Adolesc Psychopharmacol. 2013;23(2):110\u20136. https:\/\/doi.org\/10.1089\/cap.2011.0136.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"3073_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/B978-0-12-803376-0.00005-8","volume-title":"Severe neutropenia and agranulocytosis. Life Threatening effects of antipsychotic drugs","author":"J Lally","year":"2016","unstructured":"Lally J, Flanagan RJ. Severe neutropenia and agranulocytosis. Life Threatening effects of antipsychotic drugs; 2016. p. 105\u201348. https:\/\/doi.org\/10.1016\/B978-0-12-803376-0.00005-8. Retrieved from www.scopus.com"},{"key":"3073_CR7","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s12888-016-0874-x","volume":"16","author":"H Matsuura","year":"2016","unstructured":"Matsuura H, Kimoto S, Harada I, Naemura S, Yamamuro K, Kishimoto T. Lithium carbonate as a treatment for paliperidone extended-release-induced leukopenia and neutropenia in a patient with schizoaffective disorder; a case report. BMC Psychiatry. 2016;16:161.","journal-title":"BMC Psychiatry"},{"issue":"3","key":"3073_CR8","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1177\/0004867412460594","volume":"47","author":"V Raj","year":"2013","unstructured":"Raj V, Druitt T, Purushothaman S, Dunsdon J. Risperidone\/paliperidone induced neutropenia and lymphopenia. Aust N Z J Psychiatry. 2013;47(3):291\u20132.","journal-title":"Aust N Z J Psychiatry"},{"issue":"1","key":"3073_CR9","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.pnpbp.2010.09.018","volume":"35","author":"JN Kim","year":"2011","unstructured":"Kim JN, Lee BC, Choi IG, Jon DI, Jung MH. Paliperidone-induced leukopenia and neutropenia: a case report. Prog Neuro-Psychopharmacol Biol Psychiatry. 2011;35(1):284\u20135.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"1","key":"3073_CR10","doi-asserted-by":"publisher","first-page":"102.e3","DOI":"10.1016\/j.genhosppsych.2012.03.009","volume":"35","author":"G Manfredi","year":"2013","unstructured":"Manfredi G, Solfanelli A, Dimitri G, Cuomo I, Sani G, Kotzalidis GD, Girardi P. Risperidone-induced leukopenia: a case report and brief review of literature. Gen Hosp Psychiatry. 2013;35(1):102.e3\u20136. https:\/\/doi.org\/10.1016\/j.genhosppsych.2012.03.009 ISSN 0163-8343, (http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0163834312000795).","journal-title":"Gen Hosp Psychiatry"},{"key":"3073_CR11","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.2147\/NDT.S141472","volume":"13","author":"V Kattalai Kailasam","year":"2017","unstructured":"Kattalai Kailasam V, Chima V, Nnamdi U, Sharma K, Shah K. Risperidone-induced reversible neutropenia. Neuropsychiatr Dis Treat. 2017;13:1975\u20137. https:\/\/doi.org\/10.2147\/NDT.S141472.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"4","key":"3073_CR12","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1345\/aph.1G396","volume":"40","author":"P Schulte","year":"2006","unstructured":"Schulte P. Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring. Ann Pharmacother. 2006;40(4):683\u20138.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"3073_CR13","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1186\/s12888-016-1167-0","volume":"16","author":"O Ingimarsson","year":"2016","unstructured":"Ingimarsson O, Maccabe JH, Haraldsson M, J\u00f3nsd\u00f3ttir H, Sigurdsson E. Neutropenia and agranulocytosis during treatment of schizophrenia with clozapine versus other antipsychotics: an observational study in Iceland. BMC Psychiatry. 2016;16(1):441.","journal-title":"BMC Psychiatry."},{"issue":"2","key":"3073_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1055\/s-0030-1249071","volume":"43","author":"MA Rettenbacher","year":"2010","unstructured":"Rettenbacher MA, Hofer A, Kemmler G, Fleischhacker WW. Neutropenia induced by second generation antipsychotics: a prospective investigation. Pharmacopsychiatry. 2010;43(2):41\u20134.","journal-title":"Pharmacopsychiatry."},{"issue":"4","key":"3073_CR15","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/1039856213491990","volume":"21","author":"L Drew","year":"2013","unstructured":"Drew L. Clozapine and agranulocytosis: re-assessing the risks. Australas Psychiatry. 2013;21(4):335\u20137.","journal-title":"Australas Psychiatry"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-021-03073-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12888-021-03073-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-021-03073-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T18:40:49Z","timestamp":1612809649000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-021-03073-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,6]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3073"],"URL":"https:\/\/doi.org\/10.1186\/s12888-021-03073-w","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,6]]},"assertion":[{"value":"21 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written informed consent was obtained from the individual to participate and of any potentially identifiable data included in this article. This study was carried out in accordance with the recommendations of Institutional Review Board of Johns Hopkins University School of Medicine with written informed consent from all subjects.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the individual for the publication of this manuscript and of any potentially identifiable data included in this article. This study was carried out in accordance with the recommendations of Institutional Review Board of Johns Hopkins University School of Medicine with written informed consent from all subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no competing interests to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"76"}}